Skip to main content
eScholarship
Open Access Publications from the University of California

Long-term follow-up of 22 psoriatic patients treated with ixekizumab after failure of secukinumab

  • Author(s): Amschler, K
  • Phillip, S
  • Mohr, J
  • Wilsmann-Theis, D
  • Poortinga, S
  • Gerdes, S
  • Mössner, R
  • et al.
Creative Commons 'BY-NC-ND' version 4.0 license
Abstract

Switching of biologic agents in treatment of plaque psoriasis is a common strategy. Only a few studies are available on switching between IL17A-blockers. In a retrospective study, we identified 22 psoriasis patients who, after failing secukinumab as a first IL17A-blocker received ixekizumab with an observation period of at least 24 weeks. At last observation 10/22 patients had a good response (PASI75 or PASI<3) using ixekizumab therapy. None of five patients with primary non-response to secukinumab reached a good, durable response to ixekizumab. In conclusion, ixekizumab appears to be a therapeutic option as a second IL17A-blocker in psoriasis patients who did not show a primary non-response to secukinumab.

Main Content
Current View